StreetInsider.com News Articles

Guggenheim says buy this biotech stock

Thu, 18 Jun 2026 16:00:00 -0400

Guggenheim reiterated one biotech name as its top pick Wednesday after the company reported positive monotherapy data for its TL1A antibody SPY002, with efficacy and safety results the bank said align with first-generation drugs in the class.

Analyst Yatin Suneja said Spyre Therapeutics' (NASDAQ: SYRE) SPY002 produced clinical remission in 33% of patients and endoscopic improvement in 42% at 12 weeks in the SKYLINE-UC Part A study, which enrolled approximately 130 patients with ulcerative colitis.

Suneja characterized the results as "in-line, absolute efficacy with 1st gen TL1As," referencing approved or late-stage drugs including Tulisokibart, Afimkibart and Duvakitug.

Guggenheim argued that SPY002's full

Guggenheim says buy this biotech stock

Thu, 18 Jun 2026 16:00:00 -0400

Suneja characterized the results as "in-line, absolute efficacy with 1st gen TL1As," referencing approved or late-stage drugs including Tulisokibart, Afimkibart and Duvakitug.

Guggenheim argued that SPY002's full

Spyre (SYRE) PT Raised to $104 at Jones Trading

Tue, 16 Jun 2026 07:40:37 -0400

Jones Trading analyst Debanjana Chatterjee raised the price target on Spyre (NASDAQ: SYRE) to $104.00 (from $95.00) while maintaining a Buy rating.

Form 8-K Spyre Therapeutics, Inc. For: Jun 15

Mon, 15 Jun 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260615/26644490.html

Form 8-K Spyre Therapeutics, Inc. For: Jun 15

Mon, 15 Jun 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260615/26644490.html

Spyre reports positive phase 2 trial results for ulcerative colitis drug

Mon, 15 Jun 2026 08:01:48 -0400

Spyre Therapeutics Inc. (NASDAQ: SYRE) reported positive 12-week results from its Phase 2 SKYLINE trial of SPY002, an investigational anti-TL1A antibody for treating moderate-to-severe ulcerative colitis.

The trial met its primary endpoint with SPY002 showing a statistically significant 10.7-point reduction from baseline in Robart's Histopathology Index score at week 12 (p<0.0001). Secondary endpoints included a clinical remission rate of 33% by modified Mayo Score and endoscopic improvement rate of 42%.

The study enrolled 48 patients, with 35% having prior advanced therapy exposure and a mean disease duration of 7.0 years. The baseline mean RHI score was 16.9 ± 8.5, and 56% of

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Mon, 15 Jun 2026 08:00:00 -0400

SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score

Secondary endpoints included clinical remission by modified Mayo Score of 33% and endoscopic improvement of 42%

SPY002 was well tolerated with a safety profile consistent with the TL1A class

SPY002 Phase 2 results delivered within one year of Phase 1 results, highlighting continued operational excellence; on track for multiple additional readouts this year

WALTHAM, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Mon, 15 Jun 2026 08:00:00 -0400

SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score

Secondary endpoints included clinical remission by modified Mayo Score of 33% and endoscopic improvement of 42%

SPY002 was well tolerated with a safety profile consistent with the TL1A class

SPY002 Phase 2 results delivered within one year of Phase 1 results, highlighting continued operational excellence; on track for multiple additional readouts this year

WALTHAM, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 05 Jun 2026 16:01:00 -0400

WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 05 Jun 2026 16:01:00 -0400

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 05 Jun 2026 16:01:00 -0400

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 05 Jun 2026 16:01:00 -0400

Spyre (SYRE) PT Raised to $115 at Deutsche Bank

Thu, 04 Jun 2026 04:10:31 -0400

Deutsche Bank analyst David Hoang raised the price target on Spyre (NASDAQ: SYRE) to $115.00 (from $102.00) while maintaining a Buy rating.

The analyst comments: “Competitor ABVX (Not Covered) has traded down 30%+ since Monday, following a surprise safety signal for malignancy emerging from the Ph3 ABTECT maintenance trial of obefazimod in ulcerative colitis (UC), which creates an opportunity for SYRE, in our view. Heading into the readout, obefazimod had been widely praised by the sell-side for both strong efficacy (in 8-week induction therapy, which was confirmed to extend to 44-week maintenance therapy) and a pristine safety/tolerability profile. Coupled with its

Spyre (SYRE) PT Raised to $115 at Deutsche Bank

Thu, 04 Jun 2026 04:10:31 -0400

Deutsche Bank analyst David Hoang raised the price target on Spyre (NASDAQ: SYRE) to $115.00 (from $102.00) while maintaining a Buy rating.

Form 4 Spyre Therapeutics, Inc. For: Jun 03 Filed by: Sloan Sheldon

Wed, 03 Jun 2026 21:32:00 -0400

si-local-file:///var/storage/secattach/20260603/26601173.html

Form 4 Spyre Therapeutics, Inc. For: Jun 03 Filed by: Sloan Sheldon

Wed, 03 Jun 2026 21:32:00 -0400

si-local-file:///var/storage/secattach/20260603/26601173.html

Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Burrows Scott L

Wed, 03 Jun 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26601167.html

Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Burrows Scott L

Wed, 03 Jun 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26601167.html

Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Turtle Cameron

Wed, 03 Jun 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26601171.html

Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Turtle Cameron

Wed, 03 Jun 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26601171.html

Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon

Wed, 03 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260603/26599326.html

Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon

Wed, 03 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260603/26599326.html

Spyre completes enrollment in SKYWAY trial for anti-TL1A therapy SPY072

Wed, 03 Jun 2026 08:03:44 -0400

Spyre Therapeutics Inc. (NASDAQ: SYRE) completed enrollment for all sub-studies in its SKYWAY basket trial evaluating SPY072, an anti-TL1A antibody, for treatment of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

The company finished enrollment across all sub-studies in less than nine months. Spyre expects topline data for rheumatoid arthritis in the third quarter of 2026 and results for psoriatic arthritis and axial spondyloarthritis in the fourth quarter of 2026.

The SKYWAY Phase 2 trial is a randomized, placebo-controlled study examining SPY072 in patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who had inadequate responses to conventional or

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Wed, 03 Jun 2026 08:00:00 -0400

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete

Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for PsA and axSpA

Across SKYWAY and SKYLINE trials, planned ‘6 in ’26’ Phase 2 readouts enabled and on track

Preclinical data supporting SPY072 in rheumatic diseases presented at 2026 European Congress of Rheumatology (EULAR)

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Wed, 03 Jun 2026 08:00:00 -0400

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete

Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for PsA and axSpA

Across SKYWAY and SKYLINE trials, planned ‘6 in ’26’ Phase 2 readouts enabled and on track

Preclinical data supporting SPY072 in rheumatic diseases presented at 2026 European Congress of Rheumatology (EULAR)

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that